跳至主要内容
临床试验/NL-OMON40010
NL-OMON40010已完成不适用

Effects and Cost-Effectiveness of Pharmacogenetic Screening among Elderly Starters with Antidepressants: A Pragmatic Randomized Controlled Trial - Cytochrome P450-2D6 screening in elderly using antidepressants

Rijksuniversiteit Groningen0 个研究点目标入组 750 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
750

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • *Age 60 years or older
  • *Major depression according to DSM-IV criteria for which the treating psychiatrist decided to start drug treatment with either nortriptyline or venlafaxine
  • *Competent to understand the informed consent procedure

排除标准

  • *Use of clinically relevant CYP2D6 inhibitors (e.g. fluoxetine, paroxetine, quinidine, ritonavir, efavirenz)
  • *Use of clinically relevant CYP2D6 inducers (e.g. dexamethasone, rifampicine)
  • *Use of other drugs that affect plasma levels as co-medication
  • *Serious hepatic failure (ASAT/ALAT or gamma-GT * twice the maximal reference value)
  • *Patients for which drug treatment with venlafaxine is started and a GFR < 30 ml/min.
  • *Patienst with the very rare genotype: Intermediate Metabolizer with duplications (IMDUP).

研究者

发起方
Rijksuniversiteit Groningen

相似试验